Frank Oakes - President & Chief Executive Officer

Mr. Oakes has more than 30 years of management experience in aquaculture including a decade as CEO of The Abalone Farm, Inc., during which he led that company through the R&D, capitalization and commercialization phases of development to become the first profitable and largest abalone producer in the U.S.. He is the inventor of the company's patented method for non-lethal extraction of hemolymph from the keyhole limpet. He was the Principal Investigator on the company's Phase I and II SBIR grants from the NIH's Center for Research Resources, a California Technology Investment Partnership (CalTIP) grant from the Department of Commerce. He has consulted and lectured for the aquaculture industry around the world. Frank received his Bachelor of Science degree from California State Polytechnic University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance (LARTA) University's management-training program.

Darrell Brookstein - Executive VP, Corporate Development & Finance

Mr. Brookstein was Managing Director of The Nanotech Company, LLC and a director of CAG Capital. He has founded, built to profitability and been CEO of investment firms involved in securities, commodities, mining and natural resource venture capital, as well as advanced technologies. Mr. Brookstein has published several books and newsletters related to business development and investing in these fields, including The Prospector and Nanotech Fortunes. He received his BA from Duke University.

Scott Davis - Chief Financial Officer

Mr. Davis is a partner of Cross Davis & Company LLP Certified General Accountants, a firm focused on providing accounting and management services for publicly-listed companies. His experience includes CFO positions of several companies listed on the TSX Venture Exchange, and his past experience consists of senior management positions, including three years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davidson & Company LLP Chartered Accountants as an Auditor, five years with Pacific Opportunity Capital Ltd. as an Accounting Manager, and two years at Jacobson Soda and Hosak, Chartered Accountants.

Herbert S. Chow, Ph.D. - Vice President, Product Development

Dr. Chow has held key business management and product development positions in new biologic devices, clinical diagnostic and consumer diagnostic markets. He has considerable operational expertise in developing and commercializing innovative technologies, and building successful strategic partnership in the fields of medical diagnostic and therapeutic devices. Previously, he held key senior management positions with start-up biotechnology companies, as well as international pharmaceutical companies Abbott Labs and Johnson & Johnson. Dr. Chow earned his BS in Microbiology and Immunochemistry at Ohio State University and his Ph.D. in Immunopathology at the University of Illinois. In more than 25 years in the life sciences, Dr. Chow has been granted nine patents in chemical processing, microfluidic devices, liquid sensing devices and medical devices for point-of-care diagnosis.

John S. Sundsmo, Ph.D., VP, Research & IP Management

With 20+ years of leadership in biopharmaceutical companies, John's background is a unique blend of business, intellectual property and research experience gained in academia, at businesses including Collagen Corporation, Triton Biosciences/Royal Dutch Shell, Viagene, International Medical Innovations, TransCell Therapeutics and PrimeGen Biotech; and, in law firms at Christensen, O'Connor (Seattle) and Weiss, Jensen (Seattle/Portland). A registered U.S. Patent Agent since 1989; and, co-founder of five biopharmaceutical companies, he has served in research, intellectual property and business development management positions of increasing responsibility, most recently as President, PrimeGen Biotech, Inc., a stem cell company. John earned his Ph.D. in Microbiology/Immunology at the University of Washington with post-doctoral studies in Molecular Oncology at Fred Hutchinson Cancer Research Center (Seattle) and Molecular Immunology at Scripps Research Institute (La Jolla).

Catherine Brisson, Ph.D. - Executive Director, Quality Assurance & Regulatory Affairs

Dr. Brisson has more than 14 years of experience in the biotech, pharmaceutical and medical device arenas with cross-functional expertise in Quality Assurance and Regulatory Affairs providing leadership and direction over GMP, GLP & GCP operations in a clinical development and commercial setting. She has considerable operational expertise holding key positions in Quality Control, Validation and Product/Process Development areas. Previously, she held key senior management positions with start-up biotechnology companies, as well as international pharmaceutical company, Sicor Pharmaceuticals, Inc. (currently Teva Parenteral Products). Dr. Brisson earned her BS in Chemistry at North Carolina State University and her Ph.D. in Organic Chemistry at the University of North Carolina. In her more than 14 years in the life sciences, she has developed extensive experience in compliance management and assessment, assisting with the preparation and review of regulatory submissions and subsequent maintenance; as well as a strong working knowledge of global regulatory requirements.

Directors

Frank Oakes - Chairman of the Board of Directors

Darrell Brookstein

Mr. Brookstein was Managing Director of The Nanotech Company, LLC and a director of CAG Capital. He has founded, built to profitability and been CEO of investment firms involved in securities, commodities, mining and natural resource venture capital, as well as advanced technologies. Mr. Brookstein has published several books and newsletters related to business development and investing in these fields, including The Prospector and Nanotech Fortunes. He received his BA from Duke University.

Daniel E. Morse, Ph.D.

Dr. Morse is Professor of Molecular Genetics and Biochemistry at UCSB; he received his B.A. degree in Biochemistry from Harvard, and Ph. D. in Molecular Biology from Albert Einstein College of Medicine. He was awarded a Career Development Award from the National Institutes of Health and a Faculty Research Award from the American Cancer Society; honored as a Distinguished Faculty Scholar by the Woods Hole Oceanographic Institution, and as a Visiting Lecturer in Japan and the University of Paris; elected a Regents Fellow of the Smithsonian Institution; and elected a Fellow of the American Association for the Advancement of Science. Scientific American named him one of 50 leading technology pioneers of 2006 for his research on biologically inspired routes to nanostructured semiconductor thin films. He was honored as the 7th Kelly Lecturer in Materials and Chemistry by Cambridge and as the 3M Lecturer in Chemistry and Materials by the University of Vancouver. Dr. Morse is Director of the U.S. Army-sponsored UCSB-MIT-Caltech Institute for Collaborative Biotechnologies.

Malcolm Gefter, Ph. D.

Dr. Gefter is Professor of Biochemistry Emeritus at MIT. With 275 peer reviewed articles and professorships at both Columbia and MIT, his academic credentials are well established. More recently, he focused his expertise in business and pharmaceutical development, leading Praecis Pharmaceuticals as its CEO from 1989 - 2007. Dr. Gefter received his B.S. in Chemistry from University of Maryland and Ph. D. from Albert Einstein College of Medicine in Molecular Biology. He did postdoctoral work at MRC Laboratory of Molecular Biology in Genetics and Molecular Biology with Brenner and Crick and at the Pasteur Institute under Jacob.

Harvey Wright

Mr. Wright was Chief of Anesthesiology at St. John's Hospital in Jackson Hole, Wyoming. Mr. Wright was President of the Association of Nurse Anesthesiologists. He was elected to the Board of Directors of St. Johns Hospital. Mr. Wright obtained his A.D. from Ricks College.

David L. Hill, Ph. D.

Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts. He is Scientific Director of the ART Reproductive Center and is currently Assistant Clinical Professor at the David Geffen School of Medicine at UCLA. After receiving his BS in Marine Biology at Cal Poly - San Luis Obispo, CA, Dr. Hill received his MS in Biological Sciences there, then went on to a Ph.D. in Biological Sciences/Pathobiology at the University of Connecticut and post-doc Fellowship at The Dana Farber Cancer Institute (Appointment through the Department of Physiology and Biophysics, Harvard Medical School). He is listed on more than 100 peer-reviewed published papers.

CORPORATE

MANAGEMENT & DIRECTORS